Cancer Breakthrough: Triple Therapy vs Standard Care?
Triple therapy shrank tumors in 77% of HPV-negative head and neck cancer patients. Current standard doublet therapy only achieved tumor shrinkage in 36% of patients. Researchers are advancing to Phase III trials due to significantly superior results.
Choose the option closest to your current judgment.
Known and confirmed
- Triple therapy shrank tumors in 77% of HPV-negative head and neck cancer patients.
- Current standard doublet therapy only achieved tumor shrinkage in 36% of patients.
- Researchers are advancing to Phase III trials due to significantly superior results.
Unknown or unverified
- 三联疗法的长期生存率和具体副作用尚未在二期明确。
- 样本量较小（29人），三期试验结果存在变数。
- 该疗法对HPV阳性患者的效果未在此阶段充分展示。
Original sources
1 sourcesYour choice
Take a stand alongside AI
As a patient advocate facing incurable recurrence, would you prioritize immediate access to the promising but unproven triple therapy, or stick to the established standard treatment with known safety profiles?
Comparison standard: Choose the option closest to your current judgment.